Plozasiran Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Plozasiran Growth

1. First-in-Class siRNA Targeting APOC3 (Highly Differentiated Mechanism)

Plozasiran is a hepatocyte-targeted small interfering RNA (siRNA) that suppresses apolipoprotein C-III (APOC3), a key regulator of triglyceride metabolism.

• APOC3 inhibition enhances lipoprotein lipase activity and clearance of triglyceride-rich lipoproteins
• Genetic and clinical data link APOC3 reduction with lower cardiovascular risk
• Strong disease biology + RNAi platform -> high efficacy and long durability
• Positions plozasiran as a next-generation lipid-lowering therapy

2. Robust Clinical Efficacy (Deep Triglyceride Reduction)

Phase IIb and randomized trials show:

• ~50-62% triglyceride reduction vs placebo in mixed hyperlipidemia
• Up to ~57-74% reduction in severe hypertriglyceridemia (sHTG)
• ~77-78% reduction in APOC3 levels
• Among the most potent TG-lowering therapies reported
• High efficacy supports rapid adoption in high-risk patients (e.g., pancreatitis risk)

3. Durable Effect with Infrequent Dosing (Quarterly or Less)

• Clinical trials demonstrate sustained triglyceride reductions up to 48 weeks after dosing
• Administered every 3-6 months via subcutaneous injection
• Significant advantage vs daily oral or monthly injectable therapies
• Improves adherence and real-world effectiveness

4. Broad Indication Potential (sHTG, FCS, Mixed Hyperlipidemia)

Plozasiran is being developed across multiple indications:

• Severe hypertriglyceridemia (sHTG)
• Familial chylomicronemia syndrome (FCS) (ultra-rare, high-value market)
• Mixed hyperlipidemia
• Combines orphan + large population indications
• Enables both premium pricing (FCS) and volume-driven growth (mixed dyslipidemia)

Plozasiran Recent Developments

• In August 2025, Arrowhead's majority-owned subsidiary, Visirna Therapeutics, agreed to sell the exclusive license for Plozasiran in Greater China to Sanofi.

"Plozasiran Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Plozasiran for approved indication like Hyperlipidaemia, Hypertriglyceridaemia, Dyslipidaemias; as well as potential indication like Hyperlipoproteinaemia type I in the 7MM. A detailed picture of Plozasiran's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Plozasiran for approved and potential indications. The Plozasiran market report provides insights about Plozasiran's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Plozasiran performance, future market assessments inclusive of the Plozasiran market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Plozasiran sales forecasts, along with factors driving its market.

Plozasiran Drug Summary

Plozasiran is an investigational, subcutaneously administered small interfering RNA (siRNA) therapeutic designed to reduce the production of apolipoprotein C-III (APOC3), a key regulator of triglyceride metabolism, for the treatment of severe hypertriglyceridemia and related lipid disorders. By selectively silencing hepatic APOC3 mRNA through RNA interference, plozasiran enhances triglyceride clearance and reduces circulating triglyceride levels, thereby addressing a major risk factor for pancreatitis and cardiovascular disease. Clinical studies have demonstrated substantial and sustained reductions in triglycerides, along with a generally favorable safety and tolerability profile, supporting its potential as a next-generation lipid-lowering therapy. The drug remains under clinical development, with ongoing trials evaluating its long-term efficacy and broader applications across cardiometabolic indications. The report provides Plozasiran's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Plozasiran Market Report

The report provides insights into:

• A comprehensive product overview including the Plozasiran MoA, description, dosage and administration, research and development activities in approved indications like Hyperlipidaemia, Hypertriglyceridaemia, Dyslipidaemias; as well as potential indication like Hyperlipoproteinaemia type I.
• Elaborated details on Plozasiran regulatory milestones and other development activities have been provided in Plozasiran market report.
• The report also highlights Plozasiran's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Plozasiran market report also covers the patents information, generic entry and impact on cost cut.
• The Plozasiran market report contains current and forecasted Plozasiran sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Plozasiran market report also features the SWOT analysis with analyst views for Plozasiran in approved and potential indications.

Methodology:

The Plozasiran market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Plozasiran Analytical Perspective by DelveInsight

• In-depth Plozasiran Market Assessment

This Plozasiran sales market forecast report provides a detailed market assessment of Plozasiran for approved indication like Hyperlipidaemia, Hypertriglyceridaemia, Dyslipidaemias; as well as potential indication like Hyperlipoproteinaemia type I in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Plozasiran sales data uptil 2034.

• Plozasiran Clinical Assessment

The Plozasiran market report provides the clinical trials information of Plozasiran for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Plozasiran Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Plozasiran Market Potential & Revenue Forecast

• Projected market size for the Plozasiran and its key indications
• Estimated Plozasiran sales potential (Plozasiran peak sales forecasts)
• Plozasiran Pricing strategies and reimbursement landscape

Plozasiran Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Plozasiran Market positioning compared to existing treatments
• Plozasiran Strengths & weaknesses relative to competitors

Plozasiran Regulatory & Commercial Milestones

• Plozasiran Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Plozasiran Clinical Differentiation

• Plozasiran Efficacy & safety advantages over existing drugs
• Plozasiran Unique selling points

Plozasiran Market Report Highlights

• In the coming years, the Plozasiran market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Plozasiran companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Plozasiran's dominance.
• Other emerging products for Hyperlipidaemia, Hypertriglyceridaemia, Dyslipidaemias; as well as potential indication like Hyperlipoproteinaemia type I are expected to give tough market competition to Plozasiran and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Plozasiran in approved and potential indications.
• Analyse Plozasiran cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Plozasiran sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Plozasiran in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Plozasiran? How strong is Plozasiran's clinical and commercial performance?
• What is Plozasiran's clinical trial status in each individual indications such as Hyperlipidaemia, Hypertriglyceridaemia, Dyslipidaemias; as well as potential indication like Hyperlipoproteinaemia type I and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Plozasiran Manufacturers?
• What are the key designations that have been granted to Plozasiran for approved and potential indications? How are they going to impact Plozasiran's penetration in various geographies?
• What is the current and forecasted Plozasiran market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Plozasiran in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Plozasiran for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Plozasiran? What is the duration of therapy and what are the geographical variations in cost per patient?